BullFrog AI Strikes Commercial Agreement With Unnamed Pharma Firm To Deploy bfLEAP Platform

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) has entered into a commercial agreement with a top 5 global pharmaceutical company to utilize its bfLEAP platform for identifying novel drug targets in major depressive disorder (MDD). This agreement grants exclusive access to a target candidate and aims to enhance the pharmaceutical company's drug discovery and clinical development efforts. The MDD market was valued at over $8 billion in 2025 and is projected to grow at nearly 5% annually, exceeding $11 billion by 2032.